The Role of Estrogen and Testosterone in Determining Brain Blood Flow and Metabolic Regulation in Humans

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-40
SponsorUniversity of British Columbia

About this trial

Due to historical exclusion of females from research, there are gaps in the understanding of female physiology, how it differs from males, and how sex-specific hormones contribute. As a result, many diagnoses and treatments are based on male physiology and may not be appropriate or effective for females. Females consistently experience greater risk and report worse neurological outcomes in many diseases, including stroke, cardiac arrest, and dementia. As research in females progresses, differences between sexes and changes throughout the lifespan (e.g., puberty, menopause) highlight the importance of understanding the effects of sex and sex-specific hormones on the body. The brain is arguably the most important organ in the body, consuming 20% of the body's total energy. Previous research supports higher blood flow to the brain in females, and research in animals suggests hormones such as estrogen, progesterone, and testosterone are responsible. However, it is extremely difficult to isolate these hormones in humans, due to natural fluctuations (i.e., menstrual cycle). Therefore, the investigators plan to explore the direct role of these sex-specific hormones in regulating blood flow to the brain by blocking hormone production in healthy males and females and giving back testosterone and estrogen, respectively. The investigators will then conduct a range of tests to look at blood flow to the brain at rest and during various stressors. This research will provide crucial insight into how males and females differ in regulation of brain blood flow and inform new treatments and therapies to a wide range of brain injuries and diseases, improving outcomes and reducing the sex disparity in clinical pathways.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Hypertensive (≥140/90 mmHg) or hypotensive (≤90/60 mmHg)

BMI ≥ 30 kg/m2

Fasting blood glucose ≥ 100 mg/dL

Abnormal results on standard blood hematology tests (e.g., complete blood count, comprehensive metabolic panel)

Disqualifiers

None

Trial design

Design model

Single group

Treatments tested in this trial

  • GnRH antagonist

    Drug

    blockade of hormone production

  • Estradiol (E2)

    Drug

    Estrogen add-back in females

  • Testosterone

    Drug

    testosterone add-back in males

  • Anastrozole (Arimidex)

    Drug

    Prevention of testosterone conversion to estrogen in males

Treatment groups

50 Participants
are divided into 1 treatment group
Group A: Hormone ManipulationExperimental treatment 4 interventions

Trial outcomes

Primary outcomes

1

Cerebral blood flow responses to estrogen and testosterone

To determine how cerebral blood flow regulation is altered by estrogen and testosterone concentrations. Measured through doppler ultrasonography, and reported in mL/min.

Time frame
7 days
2

Cerebral metabolic changes with estrogen and testosterone

Measured as cerebral metabolic rate of oxygen consumption. Determined using arterial and internal jugular vein blood sampling coupled with doppler ultrasound, to determine metabolism directly using the Fick method.

Time frame
4 days

Secondary outcomes

1

Hormone influences on appetite sensations

How estrogen and testosterone influence appetite sensations (visual analog scale)

Time frame
7 days
2

How estrogen and testosterone influence energy intake

dietary intake, measured with self-report questionnaire

Time frame
7 days

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: